7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-[1,2,4]triazol-3-ylmethoxy)-3-phenylpyrazolo[1,5-d][1,2,4]triazine | 342652-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-[1,2,4]triazol-3-ylmethoxy)-3-phenylpyrazolo[1,5-d][1,2,4]triazine
• 英文别名: 5-Methyl-3-[2-[(1-methyl-1,2,4-triazol-3-yl)methoxy]-3-phenylpyrazolo[1,5-d][1,2,4]triazin-7-yl]-1,2-oxazole
• CAS: 342652-65-7
• 化学式: C₁₉H₁₆N₈O₂
• 分子量: 388.388
• InChiKey: LSPVUEOZCOGVFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  109
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• PYRAZOLO 1,5-D] 1,2,4]TRIAZINES FOR ENHANCING COGNITION
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP1235829A2

  公开（公告）日：2002-09-04
• US6355638B1
  申请人：——

  公开号：US6355638B1

  公开（公告）日：2002-03-12
• [EN] PYRAZOLO[1,5-D][1,2,4]TRIAZINES FOR ENHANCING COGNITION<br/>[FR] GROUPE PYRAZOLO[1,5-D][1,2,4]TRIAZINES DESTINE A AMELIORER LA COGNITION
  申请人：MERCK SHARP & DOHME

  公开号：WO2001038331A2

  公开（公告）日：2001-05-31

  The present invention provides compounds of formula (I), or a salt thereof: wherein R1 represents halogen; or C¿1-6?alkyl,C3-7cycloalkyl, C4-7cycloalkenyl, C6-8 bicycloalkyl, C6-10aryl, C3-7 heterocycloalkyl, heteroaryl or di(C1-6)alkylamino, any of which groups may be optionally substituted; L is O, S or NR?n¿ where Rn is H, C¿1-6?alkyl or C3-6cycloalkyl; W is: C1-6alkyl, C2-6alkenyl or C2-6alkynyl optionally substituted; X is NR?4R5¿; or X is a 5-membered or a 6-membered heteroaromatic ring the 5- or 6-membered heteroaromatic ring being optionally fused to a benzene or pyridine ring and the heteroaromatic ring being optionally substituted; Y is optionally branched C¿1-4?alkylene optionally substituted by an oxo group or Y is a group (CH2)jO wherein the oxygen atom is nearest the group X and j is 2, 3 or 4; and Z represents a 5-membered or a 6-membered heteroaromatic ring any of which rings may be optionally substituted; pharmaceutical compositions containing them, their use in methods of treatment, and the use of them for manufacturing treatments for enhancing cognition, particularly in Alzheimer's Disease, and corresponding methods of treatment; the compounds are ligands and inverse agonists for the GABA-A alpha 5 receptor subtype.